Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsJb pharma

    Jb Pharma

    Jump to

    • JB Pharma eyeing 12% growth, open to acquisitions, says CEO Nikhil Chopra

      Acknowledged a subdued sentiment, Chopra is confident of JB Pharma's ability to outgrow the market ‘due to its focus on progressive categories and better execution’

    • JB Pharma stock surges to 52-week high on stellar Q1 earnings show

      JB Pharma has upbeat future growth plans, targeting operating margins in the range of 26 -28 percent and taking the share of chronic therapies in its India business to 80 percent.

    • Mankind Pharma, Dr Reddy's, Torrent Pharma in race to acquire JB Pharma: Report

      The first round of bids is expected in the next few weeks and Kotak Mahindra Bank is running the sale mandate

    • JB Pharma Q3 net profit rises to Rs 134 crore

      The company reported a net profit of Rs 106 crore in the October-December period of the last fiscal.

    • JB Pharma inks Rs 964-cr licence deal with Novartis for ophthalmology brands

      As per IQVIA, MAT September, 2023 data, sales for these brands was at Rs 207.8 Crores.

    • JB Pharma Q2 results: Net Profit up 35% to Rs 150.5 crore

      The pharma company had reported a net profit of Rs 111.1 crore in the year-ago period.

    • Maharashtra GST dept inspects JB Pharma office, stock down 3%

       The inspection commenced on 25 October

    • More work needed to diagnose cardiovascular, hypertension problems: Nikhil Chopra, JB Pharma

      The CEO of JB Pharma said there was a need to augment diagnosis of cardiovascular diseases in India. He said one in four hypertension patients remains undiagnosed.

    • India Budget 2023: Pharma industry urges govt to focus on schemes for innovation, provide tax incentives on R&D

      The industry leaders have pitched for re-evaluating India’s role in the global pharmaceuticals sector with innovation and technology as cornerstone.

    • JB Pharma slashes price of critical heart failure medicine in India

      The company has slashed the price of Azmarda (Saccubutril-Valsartan), 50 mg, to Rs 39.6 per tablet as against Rs 78 per tablet earlier

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347